NCT06433050View on ClinicalTrials.gov

Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

June 30, 2027

Conditions
Hypertrophic Cardiomyopathy Without Obstruction
Interventions
DRUG

Sotagliflozin

Sotagliflozin or placebo will be administered to each participant in a cross over study design. Each participant will receive active drug and placebo with randomization of the order in which they receive them.

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Pennsylvania

OTHER